Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.

Area of Science:

• Pharmacology
• Oncology
• Drug Development

Background:

• Traditional chemotherapy dose optimization focused on maximum tolerated dose (MTD), often leading to significant toxicity.
• Emerging targeted therapies and immunotherapies allow for efficacy at lower doses, below the MTD, with reduced side effects.
• Recent FDA guidance emphasizes improved dose optimization strategies in oncology drug development.

Purpose of the Study:

• To present a novel framework for tailored dose optimization in oncology drug development.
• To categorize oncology molecules into four distinct classes based on mechanism of action and clinical activity.
• To discuss unique dose optimization considerations for each molecular class.

Main Methods:

• Categorization of oncology molecules into four classes: Class 1 (small molecule targeted therapies, antibody-drug conjugates), Class 2 (large molecule antagonists), Class 3 (cancer immunotherapy agonists), and Class 4 (molecules with limited single-agent activity).
• Discussion of specific dose optimization strategies for each class, supported by case examples.
• Proposal of using proof of activity as a criterion for initiating dose expansion.

Main Results:

• A proposed framework for classifying oncology drugs to guide dose optimization.
• Identification of distinct dose optimization considerations for each of the four molecular classes.
• Emphasis on integrating preclinical data, disease knowledge, and clinical measurements for robust decision-making.

Conclusions:

• A new, class-based approach to oncology dose optimization can enhance efficacy and minimize toxicity.
• Utilizing proof of activity as a gate for dose expansion improves decision-making and resource allocation.
• Quantitative pharmacology and statistical modeling are crucial for optimizing oncology drug doses.